ID:S01
Therapeutic Strategy:Anti-inflammatory
Synonyms:inflammatory
Related Targets:cyclo-oxygenase; proinflammatory cytokine; oxygen-free radicals; lipoxygenase; neutrophil chemotaxis; mast cell activation; nuclear factor-κB activation (NF-κB); PPARγ
Related Drugs:5-Aminosalicylates (5-ASAs); corticosteroids
Mechanism:Crohn's disease and ulcerative colitis are the two main components of inflammatory bowel disease.1 Crohn's disease is a relapsing inflammatory disease, mainly affecting the gastrointestinal tract, and frequently presents with abdominal pain, fever, and clinical signs of bowel obstruction or diarrhoea with passage of blood or mucus, or both.augment peroxisome proliferator-activated receptor-γ (PPARγ) expression and promote PPARγ translocation from the cytoplasm to the nucleus where they result in activation of peroxisome-proliferator hormone response element-driven genes to suppress colitis activity
Related Literature
Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
📅 Publication Date: 2025-07-23
📖 Source: Alimentary pharmacology & therapeutics
# PMID: 12950415
📖 Source: Alimentary pharmacology & therapeutics
# PMID: 12950415
A series of epidemiological, experimental and preliminary clinical trials strongly suggest that mesalazine or 5-aminosalicyclic acid (5-ASA) may have antineoplastic and potentiall…
Crohn's disease.
📅 Publication Date: 2025-07-23
📖 Source: Lancet (London, England)
# PMID: 22914295
📖 Source: Lancet (London, England)
# PMID: 22914295
Crohn's disease is a relapsing systemic inflammatory disease, mainly affecting the gastrointestinal tract with extraintestinal manifestations and associated immune disorders. Geno…
Aminosalicylates for induction of remission or response in Crohn's disease.
📅 Publication Date: 2025-07-23
📖 Source: The Cochrane database of systematic reviews
# PMID: 27372735
📖 Source: The Cochrane database of systematic reviews
# PMID: 27372735
BACKGROUND: Randomized trials investigating the efficacy of aminosalicylates for the treatment of mildly to moderately active Crohn's disease have yielded conflicting results. A s…